Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
December 05, 2017 08:15 ET
|
Galectin Therapeutics Inc.
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line...
Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
December 04, 2017 16:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, will issue a press release announcing...